Abstract
Circulating Tumor Cells (CTCs) are a valuable prognostic factor in several solid tumors. By understanding the biological characteristics of CTCs we could better understand the biology of metastasis. CTCs usually adopt a dormant state that is believed to be a strategy to survive in extreme conditions. To enter a dormant state, CTCs undergo numerous phenotypic, genetic and functional mutations that significantly affect the efficacy of the therapies used to kill dormant CTCs. Hence, understanding the biological events involved in the dormancy process of CTCs would allow the identification of new therapeutic targets. Some experimental studies or preclinical models have explored these biological events, as well as the molecular factors that contribute to the maintenance of and release from dormancy. However, few studies have assessed the effects of anticancer therapies on dormant cells. This study reviews current the data currently available on cell dormancy mechanisms in prostate cancer, with a special focus on the functional, genetic and phenotypic plasticity of CTCs and their potential implications in the clinical and therapeutic management of prostate cancer.
Keywords: CTCs, dormancy, EMT, miRNA, prostate cancer.
Current Drug Targets
Title:Dormant Circulating Tumor Cells in Prostate Cancer: Therapeutic, Clinical and Biological Implications
Volume: 17 Issue: 6
Author(s): Maria J. Alvarez-Cubero, Fernando Vázquez-Alonso, Ignacio Puche-Sanz, F. Gabriel Ortega, M. Martin-Prieto, José L. Garcia-Puche, Manrique Pascual-Geler, José A. Lorente, José M. Cozar-Olmo and Maria J. Serrano
Affiliation:
Keywords: CTCs, dormancy, EMT, miRNA, prostate cancer.
Abstract: Circulating Tumor Cells (CTCs) are a valuable prognostic factor in several solid tumors. By understanding the biological characteristics of CTCs we could better understand the biology of metastasis. CTCs usually adopt a dormant state that is believed to be a strategy to survive in extreme conditions. To enter a dormant state, CTCs undergo numerous phenotypic, genetic and functional mutations that significantly affect the efficacy of the therapies used to kill dormant CTCs. Hence, understanding the biological events involved in the dormancy process of CTCs would allow the identification of new therapeutic targets. Some experimental studies or preclinical models have explored these biological events, as well as the molecular factors that contribute to the maintenance of and release from dormancy. However, few studies have assessed the effects of anticancer therapies on dormant cells. This study reviews current the data currently available on cell dormancy mechanisms in prostate cancer, with a special focus on the functional, genetic and phenotypic plasticity of CTCs and their potential implications in the clinical and therapeutic management of prostate cancer.
Export Options
About this article
Cite this article as:
Alvarez-Cubero J. Maria, Vázquez-Alonso Fernando, Puche-Sanz Ignacio, Ortega Gabriel F., Martin-Prieto M., Garcia-Puche L. José, Pascual-Geler Manrique, Lorente A. José, Cozar-Olmo M. José and Serrano J. Maria, Dormant Circulating Tumor Cells in Prostate Cancer: Therapeutic, Clinical and Biological Implications, Current Drug Targets 2016; 17 (6) . https://dx.doi.org/10.2174/1389450116666150309121346
DOI https://dx.doi.org/10.2174/1389450116666150309121346 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects
Current Medicinal Chemistry The Activity of Titanocene T Against Xenografted Caki-1 Tumors
Letters in Drug Design & Discovery Anticancer Potential and Molecular Targets of Pristimerin: A Mini- Review
Current Cancer Drug Targets Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy
Current Cancer Drug Targets P2X7 Receptor Orchestrates Multiple Signalling Pathways Triggering Inflammation, Autophagy and Metabolic/Trophic Responses
Current Medicinal Chemistry Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Histone Variants and Composition in the Developing Brain: Should MeCP2 Care?
Current Topics in Medicinal Chemistry Microfluidic Devices for Circulating Tumor Cells Isolation and Subsequent Analysis
Current Pharmaceutical Biotechnology Fatty Acid-Binding Proteins at a Glance
Protein & Peptide Letters Proteomic Analysis of Mitochondria in Raji Cells Following Exposure to Radiation: Implications for Radiotherapy Response
Protein & Peptide Letters A comparative <i>in vivo</i> Evaluation of Anti-Alzheimer Activity of Bacopa Extract and its Solid Lipid Nanoparticles
Current Bioactive Compounds LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets Function and Molecular Mechanism of Tumor-Targeted Peptides for Delivering Therapeutic Genes and Chemical Drugs
Mini-Reviews in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Advances in Methods for Therapeutic Peptide Discovery, Design and Development
Current Pharmaceutical Biotechnology MicroRNAs and Major Blood-borne Infectious Viral Diseases
MicroRNA Targeted Therapy of Multiple Myeloma: The Changing Paradigm at the Beginning of the New Millennium
Current Cancer Drug Targets Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Occurrence, Functions and Biological Significance of Arginine-Rich Proteins
Current Protein & Peptide Science